Today: 28 February 2026
Subscribe
Browse Category

NYSE:ELV 21 October 2025 - 31 December 2025

Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)

Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)

Elevance Health shares held near $360.52 on Dec. 12 after jumping 5.6% Thursday, breaking above their 200-day moving average. The US Senate failed overnight to extend enhanced ACA subsidies, raising the risk of higher premiums for about 24 million Americans in 2026. Congress is not expected to revisit the issue until January. ELV’s 52-week range spans $273.71 to $458.75.
12 December 2025
Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets

Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets

Elevance Health shares traded near $331 early December 3, about 30% below their 52-week high despite a strong Q3 earnings report. The stock is down 18% over the past year, underperforming the S&P 500. Q3 operating revenue rose 12% to $50.1 billion, with net income up nearly 18% to $1.2 billion. Shares fell 2.5% at the start of December before stabilizing.
3 December 2025
·
Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Elevance Health reported Q3 2025 adjusted earnings of $6.03 per share, beating analyst estimates by over $1. Revenue reached $50.1 billion, up 12% year-over-year and ahead of forecasts. Shares jumped as much as 7% pre-market on Oct. 21 before settling near the prior close. The company reaffirmed its full-year outlook and kept costs slightly below expectations.
21 October 2025
····
1 2
Go toTop